The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)
ASCO GU 2026 Prostate Cancer
- ASCO GU 2026: Imaging Meets Genomics in Treatment-Naïve Prostate Cancer: SUVmax on PSMA PET as a Biomarker of Genomic Classifier Risk
- ASCO GU 2026: Community Social Vulnerability and Clinical Risk-Based Care Implementation for Black Men with Prostate Cancer Treated in
- ASCO GU 2026: Physician Perspectives on the Implementability of a Cardiovascular Risk Score for Prostate Cancer: A PRISM-guided Evaluation.
- ASCO GU 2026: OPTIMAS: A Phase II Randomized, Decentralized, De-Escalation Trial in Patients with mHSPC Achieving Optimal PSA Response
- ASCO GU 2026: Prognostic Significance of Depressive Symptoms in Men with Advanced Prostate Cancer: Results from the IRONMAN Registry
ASCO GU 2026 Bladder Cancer
- ASCO GU 2026: Induction Ipilimumab + Nivolumab Followed by Consolidating Chemoradiotherapy as Bladder-Sparing Treatment in Stage II/III Urothelial Carcinoma of the Bladder: The Phase 2 Indi-Blade Trial
- ASCO GU 2026: Discussant: The Era of ADCs for Urothelial Carcinoma Continues
- ASCO GU 2026: Discussant: RETAIN trials and IMvigor011 trial
- ASCO GU 2026: Circulating Tumor DNA Analysis from the Prospective pT0 Study of Systematic Endoscopic Evaluation in Patients Undergoing Radical Cystectomy for Bladder Cancer
- ASCO GU 2026: Detecting FGFR3 Genomic Alterations in Liquid Biopsies from Patients with Clinically Advanced Urothelial Bladder Cancer
ASCO GU 2026 Kidney Cancer
- ASCO GU 2026: Discussant: Prevention to Progression – Targeting Foundational Biology in RCC
- ASCO GU 2026: Emerging Tools in Imaging in Renal Cell Carcinoma
- ASCO GU 2026: Imaging for Renal Cell Carcinoma: Current State of the Art
- ASCO GU 2026: Efficacy and Safety of Avelumab + Axitinib Versus Sunitinib in Patients with Very Favorable Risk Advanced RCC: Subgroup Analysis from the JAVELIN Renal 101 Trial
- ASCO GU 2026: Characterization of Depth and Durability of Response in Patients with Previously Untreated Advanced RCC Who Received Cabozantinib + Nivolumab: Long-Term Follow-up and Exploratory Analysis of CheckMate 9ER
ASCO GU 2026 Upper Tract Urothelial Carcinoma
- ASCO GU 2026: ECOG ACRIN EA8291 Cohort C: A Phase II Trial of Neoadjuvant Gemcitabine/Durvalumab in Patients with High Grade UTUC Ineligible for Cisplatin-Based Chemotherapy
- ASCO GU 2026: A Phase II Study Evaluating the Efficacy and Safety of Perioperative EV + Toripalimab Combined with Endoscope-Based Kidney-Sparing Surgery for Patients with High-Risk UTUC (WUTSUP-04EV-JS001)
ASCO GU 2026 Penile, Urethral, Testicular, and Adrenal Cancers
- ASCO GU 2026: Discussant: miR-371a-3p for MRD Detection in Clinical Stage I Testicular Germ Cell Tumors
- ASCO GU 2026: REJOICE-PanTumor01: A Phase 2 Signal-Seeking Study of Raludotatug Deruxtecan in Patients with Advanced or Metastatic Gynecologic or Genitourinary Tumors
- ASCO GU 2026: A Phase II Trial of Cabozantinib in Relapsed Refractory Germ Cell Tumors
- ASCO GU 2026: Initial Results from CLIMATE (ANZUP 1906): A Prospective Cohort Study Assessing the Clinical Utility of miR-371a-3p as a Marker of Minimal Residual Disease in CS1 Testicular Germ Cell Tumor
ASCO GU 2026 Press Releases
- WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
- Bayer’s XOFIGO® (Radium-223 Dichloride) plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases
- Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026
- New Real‑world Data Reinforce Earlier Use of Pluvicto™ Before Chemotherapy in Metastatic Castration-Resistant Prostate Cancer
- Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium